Clinical Report: Transcription Factor Dysregulation in Multiple Myeloma: An Overview

Background

Multiple myeloma is a prevalent hematological malignancy characterized by the clonal proliferation of plasma cells in the bone marrow. Despite advancements in treatment, MM remains incurable due to its genetic and transcriptional heterogeneity. Understanding the role of transcription factors in MM is crucial for developing novel therapeutic strategies.

Data Highlights

No numerical data or trial data provided in the source material.

Key Findings

• Transcriptional dysregulation is a hallmark of oncogenesis in multiple myeloma.
• Key transcription factors such as IRF4 and MYC play central roles in myeloma cell survival and drug resistance.
• Recent advances have reshaped the view of TFs as potential therapeutic targets in MM.
• Super-enhancers enriched in transcription factors can aberrantly activate oncogenes in cancer.
• Pioneer transcription factors can initiate chromatin opening, influencing gene expression in MM.

Clinical Implications

The identification of transcription factors as potential therapeutic targets may lead to innovative treatment strategies for multiple myeloma. Understanding their roles in drug resistance could inform the development of more effective therapies.

Conclusion

Transcription factors are critical in the pathobiology of multiple myeloma.

Related Resources & Content

1. Frontiers in Immunology, 2026 -- The mechanisms of regulatory T cells in the immune microenvironment of multiple myeloma and clinical significance
2. Blood Cancer Journal, 2012 -- The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies
3. Blood Cancer Journal, 2024 -- Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells
4. Haematologica, 2023 -- Treatment of Multiple Myeloma: ASCO Living Guideline
5. Haematologica, 2023 -- Mechanistic link to transcription factor (TF) dysregulation and current therapies
6. Blood Cancer Journal — An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics
7. Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2)
8. Treatment of Multiple Myeloma: ASCO Living Guideline | ASCO Publications
9. Early View | Haematologica
10. American Journal of Hematology | Blood Research Journal | Wiley Online Library